Blood Levels of Haloperidol and Thioridazine During Maintenance Neuroleptic Treatment of Schizophrenic Outpatients

  title={Blood Levels of Haloperidol and Thioridazine During Maintenance Neuroleptic Treatment of Schizophrenic Outpatients},
  author={Alla Shvartsburd and C Sajadi and V Morton and Moshen Mirabi and Jack Gordon and R. C. Smith},
  journal={Journal of Clinical Psychopharmacology},
Plasma and red blood cell levels of haloperidol, thioridazine, and thioridazine's main metabolite mesoridazine were measured in schizophrenic outpatients during treatment with fixed doses of haloperidol or thioridazine for several months. These drug levels were compared to those in schizophrenic inpatients treated with fixed doses of the same neuroleptics. There were large interpatient variations in plasma and red blood cell levels at a given dose for schizophrenic outpatients as well as for… 

Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients

The potential importance of neuroleptic activity measures in the management of schizophrenia warrants attention to the methods for assessing neuroleptic bioactivity and stability of neuroleptic

The Bioavailability and Pharmacokinetics of Oral and Depot Intramuscular Haloperidol in Schizophrenic Patients

Clinical results, and not drug plasma concentrations, are the primary determinant of dose level, especially since haloperidol decanoate is given q28d, and the appropriate method for determining the proper dose is to start low and to increase gradually as required by the patient's symptoms.

Plasma Level Monitoring of Antipsychotic Drugs Clinical Utility

  • S. Dahl
  • Psychology, Medicine
    Clinical pharmacokinetics
  • 1986
There is no evidence that plasma concentration monitoring of antipsychotic drugs may significantly reduce the incidence of tardive dyskinesia, and plasma level monitoring of thioridazine and its metabolites appears to have no clinical value.

Thioridazine for schizophrenia.

Although there are shortcomings, there appears to be enough consistency over different outcomes and periods to confirm that thioridazine is an antipsychotic of similar efficacy to other commonly used antipsychotics for people with schizophrenia.

Update on psychotropic medication use in renal disease.

This review, which is intended as a resource for consultation psychiatrists, discusses pharmacokinetic considerations and provides information about the use of individual psychotropic medications in patients with renal disease.

Antipsychotic agents: a clinical update.

Defining and assessing adherence to oral antipsychotics: a review of the literature.

Suggestions for consensus development are made, including the use of recommended terminology for different subject samples, the increased use of objective or direct measures, and the inclusion in all studies of an estimate of the percentage of medication taken as prescribed in an effort to increase comparability among studies.

Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.

No clear evidence that haloperidol was superior to low-potency antipsychotic drugs in terms of clinical response was found and there was also no clear evidence of benefit for either group in acceptability of treatment with equivocal results.